Immunotherapeutic polyoma and human papilloma virus-like particles

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 303-312

  Ramqvist, Torbjörn ^a   Dalianis, Tina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer therapy; Human papillomavirus; Immune therapy; Polyomavirus; Vaccine; Virus like particle

Indexed keywords

ANTIBODY; CANCER VACCINE; CAPSID PROTEIN; CAPSID PROTEIN L1; CAPSID PROTEIN L2; CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 PROTEIN VP2 FUSION PROTEIN; EPITOPE; GLUTATHIONE TRANSFERASE PROTEIN VP1 FUSION PROTEIN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; PROTEIN E6; PROTEIN E7; PROTEIN L1 E7 FUSION PROTEIN; PROTEIN L2 E7 FUSION PROTEIN; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; STREPTAVIDIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; BACULOVIRUS; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG STRUCTURE; ESCHERICHIA COLI; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNITY; INSECT; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS; YEAST;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CAPSID PROTEINS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; POLYOMAVIRUS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VIRION;

EID: 77953452449     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.303     Document Type: Review

References (81)

1. Verma I, Weitzman M: Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74, 711-738 (2005).
2. Warrington K, Herzog R: Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 119, 571-603 (2006).
3. Young LS, Searle PF, Onion D, Mautner V: Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 208, 299-318 (2006). (Pubitemid 43126122)
4. Mountain A: Gene therapy: the first decade. Trends Biotechnol. 18, 119-128 (2000).
5. Speck LM, Tyring SK: Vaccines for the prevention of human papillomavirus infections. Skin Therapy Lett. 11(6), 1-3 (2006).
6. Schmiedeskamp MR, Kockler DR: Human papillomavirus vaccines. Ann. Pharmacother. 40(7-8), 1344-1352 (2006).
7. Lin YY, Alphs H, Hung CF, Roden RB, Wu TC: Vaccines against human papillomavirus. Front. Biosci. 12, 246-264 (2007).
8. Tegerstedt K, Lindencrona JA, Curcio C et al.: A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res. 65(13), 5953-5957 (2005). ■ Demonstrates the efficiency of virus-like particles (VLPs) carrying tumor antigens as vaccines against nonviral tumors.
9. Kimchi-Sarfaty C, Gottesman MM: SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr. Pharm. Biotechnol. 5(5), 451-458 (2004).
10. Chackerian B, Lowy DR, Schiller JT: Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108(3), 415-423 (2001). ■ Demonstrates the ability to induce autoantibodies using conjugated VLPs.
11. Maurer P, Jennings GT, Willers J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35(7), 2031-2040 (2005).
12. Palkova Z, Adamec T, Liebl D, Stokrova J, Forstova J: Production of polyomavirus structural protein VP1 in yeast cells and its interaction with cell structures. FEBS Lett. 478(3), 281-289 (2000). (Pubitemid 30621632)
13. Forstova J, Krauzewicz N, Wallace S et al.: Cooperation of structural proteins during late events in the life cycle of polyomavirus. J. Virol. 67(3), 1405-1413 (1993). (Pubitemid 23067647)
14. Salunke DM, Caspar DL, Garcea RL: Self-assembly of purified polyomavirus capsid protein VP1. Cell 46(6), 895-904 (1986).
15. Chen XS, Casini G, Harrison SC, Garcea RL: Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. 307(1), 173-182 (2001).
16. Fernandez-San Millan A, Ortigosa SM, Hervas-Stubbs S et al.: Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J. 6, 427-441, (2008). (Pubitemid 351670277)
17. Brinkman M, Walter J, Grein S et al.: Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol. Immunother. 54(6), 611-622 (2005).
18. Heidari S, Krauzewicz N, Kalantari M, Vlastos A, Griffin BE, Dalianis T: Persistence and tissue distribution of DNA in normal and immunodeficient mice inoculated with polyomavirus VP1 pseudocapsid complexes or polyomavirus. J. Virol. 74, 11963-11965 (2000).
19. Tegerstedt K, Andreasson K, Vlastos A, Hedlund KO, Dalianis T, Ramqvist T: Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several ceil types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J. Gen. Virol. 84, 3443-3452 (2003).
20. Greenstone HL, Nieland JD, de Visser KE et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95, 1800-1805 (1998). ■■ Early demonstration of chimeric papillomavirus-like particles as immunogens.
21. Tegerstedt K, Franzén A, Andreasson K et al.: Murine polyomavirus 'virus-like' particles as vectors for gene and immune therapy and as vaccines against viral infections and cancer. Anticancer Res. 25(4), 2601-2608 (2005).
22. Berke Z, Dalianis T: Studies on polyomavirus persistence and polyomavirus-induced tumor development in relation to the immune system. Adv. Cancer Res. 79, 249-276 (2000).
23. Cole CN: Polyomavirinae: the viruses and their replication. In: Virology (3rd Edition). Fields B, Knipe DM, Howley PM (Eds). Lippincott-Raven, New York, NY, USA, 2121-2174 (1996).
24. Ramqvist T, Reinholdsson G, Carlquist M, Bergman T, Dalianis T: A single peptide derived from the sequence common to polyoma small and middle T-antigen induces immunity against polyoma tumors. Virology 172(1), 359-362 (1989). ■ First paper to our knowledge demonstrating tumor immunity by immunizing with a peptide from a virus tumor antigen.
25. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapaport TA: Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 22, 4346-4355 (2003). (Pubitemid 37087189)
26. Mannova P, Liebl D, Krauzewicz N et al.: Analysis of mouse polyomavirus mutants with lesions in the minor capsid proteins. J. Gen. Virol. 83, 2309-2319 (2002).
27. Brady JN, Consigli RA: Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J. Virol. 27, 436-442 (1978). ■■ Original article demonstrating that the major capsid protein VP1 can spontaneously self assemble into VLPs.
28. Sasnauskas K, Bulavaite A, Hale A et al.: Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 45(4-6), 308-317 (2002). (Pubitemid 36173440)
29. Kilham L, Murphy HW: A pneumotropic virus isolated from C3H mice carrying the Bittner milk agent. Proc. Soc. Exp. Biol. Med. 82, 133-137 (1953).
30. Greenlee JE, Clawson SH, Phelps RC, Stroop WG: Distribution of K-papovavirus in infected newborn mice. J. Comp. Pathol. 111(3), 259-268 (1994).
31. Mayer M, Dörries K: Nucleotide sequence and genome organization of the murine polyomavirus, Kilham strain. Virology 181(2), 469-480 (1991).
32. Viscidi R, Clayman B: Serological cross reactivity between polyomavirus capsids. Adv. Exp. Med. Biol. 577, 73-84 (2006).
33. Allander T, Andreasson K, Gupta S et al.: Identification of a third human polyomavirus. J. Virol. 81,4130-4136 (2007).
34. Gaynor AM, Nissen MD, Whiley DM et al.: Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 3(5), E64 (2007).
35. Feng H, ChudaM, Chang Y, Moore PS: Clonal Integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866), 1096-1100 (2008). (Pubitemid 351300792)
36. Howely PM, Lowy DR: Papillomaviruses and their replication. In: Virology (Volume 2). Howely PM (Ed.). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2197-2229 (2001).
37. zur Hausen H: Papillomaviruses and cancer:from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350 (2002).
38. Syrjanen SM and Syrjanen KJ: New concepts on the role of human papillomavirus in cell regulation. Ann. Med. 31, 175-187, 1999.
39. Kirnbauer R, Taub J, Greenstone H et al.: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67(12), 6929-6936 (1993).
40. Qi YM, Peng SW, Hengst K et al.: Epithelial cells display separate receptors for papillomavirus VLPs for soluble L1 protein. Virology 216, 35-45, 1996.
41. Volpers C, Unckel F, Schirmacher P, Streek R, Sapp M: Binding and internalization of human papillomavirus type 33 virus like particles by eukaryotic cells. J. Virol. 69, 3258-3264 (1995).
42. Lindahl U, Kusche-Gullberg M, Kjellen L: Regulated diversity of heparan sulfate. J. Biol. Chem. 273, 24979-24982 (1998).
43. de Witte L, Zoughlami Y, Aengeneyndt B, David G, van Kooyk Y, Gissmann L, Geijtenbeek TB: Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology 212(9-10), 679-691 (2007). (Pubitemid 350246260)
44. Giroglou T, Florin L, Schäfer F, Streeck RE, Sapp M: Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75(3), 1565-1570 (2001).
45. Heidari S, Vlastos A, Ramqvist T et al.: Immunization of T-cell deficient mice against polyomavirus infection using viral pseudocapsids or temperature sensitive mutants. Vaccine 20, 1571-1578 (2002). (Pubitemid 34169797)
46. Vlastos A, Andreasson K, Tegerstedt K et al.: VP1 pseudocapsids, but not a glutathione-5-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model. J. Med. Virol. 70, 293-300 (2003).
47. Villa LL, Costa RL, Petta CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005). ■■ Successful vaccination in humans against human papillomavirus (HPV) type 6, 11, 16 and 18 with VLPs.
48. Koutsky LA, Ault Ka, Wheeler CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002). ■■ First major clinical trial of a HPV VLP-based vaccine.
49. Harro CD, Pang YY, Roden RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L virus-like particle vaccine. J. Natl Cancer Inst. 93(4), 284-292 (2001).
50. Pinto LA, Viscidi R, Harro CD et al.: Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353(2), 451-462 (2006).
51. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
52. Cadman L: The future of cervical cancer prevention: human papillomavirus vaccines. J. Fam. Health Care 18(4), 131-132 (2008).
53. Liu WJ, Gissmann L, Sun XY et al.: Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 227(2), 474-483 (1997).
54. Pastrana DV, Gambhira R, Buck CB et al.: Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337(2), 365-372 (2005).
55. Roden RB, Yutzy WHT, Fallon R et al.: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270(2), 254-257 (2000). (Pubitemid 30333671)
56. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T: Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 80, 841-846 (2008).
57. Slupetzky K, Gambhira R, Culp TD et al.: A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25(11), 2001-2010 (2007).
58. Vlastos Franzén A, Tegerstedt K, Hollanderovi D, Forstová J, Ramqvist T, Dalianis T: Murine polyomavirus VP1 virus-like particles immunize against some polyomvirus induced tumors. In Vivo 19(2), 323-326 (2005). (Pubitemid 40467615)
59. Chen L, Fluck M: Kinetic analysis of the steps of the polyomavirus lytic cycle. J. Virol. 75, 8368-8379 (2001). (Pubitemid 32768941)
60. ink4a immunohistochemistry staining predicts response to radiotherapy and is is similar to human papilloma virus (HPV) detection by PCR a favourable prognostic factor in tonsillar carcinoma. Anticancer Research. 4375-4383 (2005).
61. Hildesheim A, Herrero R, Wacholder S et al.: Effect of human papillomavirus 16/18 Ll viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7), 743-753 (2007).
62. Gedvilaite A, Frommel C, Sasnauskas K et al.: Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273 (1), 21-35 (2000). (Pubitemid 30602004)
63. Munger K, Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res. 89(2), 213-228 (2002). (Pubitemid 35351540)
64. Wakabayashi MT, DA Silva DM, Potkul RK, Kast WM: Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 45(4-6), 300-307 (2002).
65. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L: Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch. Med. Res. 30(4), 269-274 (1999).
66. Kaufmann AM, Nieland J, Schinz M et al.: HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int. J. Cancer 92(2), 285-293 (2001).
67. Kaufman AM, Nieland JD, Jochmus I et al.: Vaccination trial with HPV16 L1E/ chimeric virus-like particles in women suffering from high grade intraepithelial neoplasia (CIN 2/3). Int. J. Cancer 121, 2794-2800 (2007).
68. Da Silva DM, Schiller JT, Kast WM: Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21(23), 3219-3227 (2003).
69. Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
70. Kiessling R, Wei WZ, Herrmann F et al.: Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 85, 101-144 (2002).
71. Andreasson K, Tegerstedt K, Eriksson O et al.: Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumours. Int J. Cancer 124(1), 150-156 (2008).
72. Lenz P, Day PM, Pang YY et al.: Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166(9), 5346-5355 (2001).
73. Lenz P, Lowy DR, Schiller JT: Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol. 35(5), 1548-1556 (2005).
74. Gedvilaite A, Dorn DC, Sasnauskas K et al.: Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 354(2), 252-260 (2006).
75. Bickert T, Wohlleben G, Brinkman M et al.: Murine polyomavirus-like particles induce maturation of bone marrow-derived dendritic cells and proliferation of T cells. Med. Microbiol. Immunol. (Berl.) 196(1), 31-39 (2007).
76. Tegerstedt K, Franzén A, Ramqvist T, Dalianis T: Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles (VLPs) efficiently prevent outgrowth of a Her2/neu expressing tumor without inducing high anti-VLP serum titers. Cancer Immunol. Immunotherapy 56(9), 1335-1344, (2007).
77. Lenz P, Thompson CD, Day PM et al.: Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. 106(3), 231-237 (2003).
78. Fausch SC, Da Silva DM, Kast WM: Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 63(13), 3478-3482 (2003).
79. Li Q, Cao C, Chackerian B et al.: Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci. 5, 21 (2004).
80. Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT: Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J. Virol. 78(8), 4037-4047 (2004). (Pubitemid 38437210)
81. Chackerian B, Lenz P, Lowy DR, Schiller JT: Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169(11), 6120-6126 (2002). (Pubitemid 36903455)